drugset / Trial / NCT02661217

Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event

NCT02661217

Phase 4 Completed 1002 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupSingle-blindSupportive care

Summary

To explore two modalities of treatment initiation (Pre-discharge, and Post-discharge) with LCZ696 in HFrEF patients following stabilization after an ADHF episode.

Timeline

Start
2016-02-12
Primary completion
2018-02-20
Completion
2018-06-20

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject LCZ696 Unknown 200 mg Oral